{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:07:23Z","timestamp":1790615243818,"version":"4.1.0"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[1992,7,1]],"date-time":"1992-07-01T00:00:00Z","timestamp":709948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[1992,7]]},"abstract":"<jats:p>Rubella virus (RV)-specific immunoglobulin G antibodies were studied by enzyme-linked immunosorbent assay (ELISA) techniques in sera from RV (RA 27\/3)-vaccinated individuals, patients experiencing natural RV infection, congenital rubella syndrome patients, and individuals failing to respond to repeated RV immunization. Results obtained by using whole-RV ELISAs (detergent-solubilized M33 strain or intact Gilchrist strain) and hemagglutination inhibition (HAI) and neutralization (NT) assays were compared with results obtained with the same sera by using ELISAs employing a synthetic peptide, BCH-178, representing a putative neutralization domain on the RV E1 protein. Murine RV E1-specific monoclonal antibodies with HAI and NT activities exhibited strong reactivity in ELISAs with BCH-178 peptide. In sera from RA 27\/3-vaccinated individuals collected at 0 (prevaccine), 1, 2, 3, 4, 5, 6, 12, and 24 to 52 weeks postvaccine, the development of E1-peptide-reactive antibodies closely paralleled increases in RV-specific antibodies measured by whole-RV ELISAs and HAI and NT assays. Similarly, sequential serum samples obtained from patients during acute and convalescent phases of natural RV infection showed a coordinate increase in RV-specific antibodies as measured by whole-RV and peptide ELISAs. Conversely, congenital rubella syndrome patient sera, although exhibiting high levels of antibody in whole-RV ELISAs, had little or no antibody directed to the neutralization domain peptide. Sera from patients failing to respond to repeated RV immunization contained very low levels of RV-specific antibody in all ELISAs. Our results that the sequence represented by BCH-178 peptide may be a previously unidentified neutralization epitope for human antibodies on the RV E1 protein and may prove useful in determining effective RV immunity.<\/jats:p>","DOI":"10.1128\/jcm.30.7.1841-1847.1992","type":"journal-article","created":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T23:50:54Z","timestamp":1578268254000},"page":"1841-1847","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":50,"title":["Characterization of rubella virus-specific antibody responses by using a new synthetic peptide-based enzyme-linked immunosorbent assay"],"prefix":"10.1128","volume":"30","author":[{"given":"L A","family":"Mitchell","sequence":"first","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of British Columbia, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of British Columbia, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of British Columbia, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"D\u00e9carie","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of British Columbia, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J","family":"Tingle","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of British Columbia, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Zrein","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of British Columbia, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Lacroix","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of British Columbia, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.30.7.1841-1847.1992","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.30.7.1841-1847.1992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T23:09:54Z","timestamp":1646435394000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.30.7.1841-1847.1992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,7]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1992,7]]}},"alternative-id":["10.1128\/jcm.30.7.1841-1847.1992"],"URL":"https:\/\/doi.org\/10.1128\/jcm.30.7.1841-1847.1992","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,7]]},"assertion":[{"value":"1992-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}